Despite its promise, Casgevy’s high cost, estimated at roughly $2 million per patient, limits its accessibility.
Despite its promise, Casgevy’s high cost, estimated at roughly $2 million per patient, limits its accessibility. This concern is particularly acute in low- and middle-income countries where the necessary technology and healthcare infrastructure may not be readily available. The high price and the requirement for specialized medical procedures make it challenging to scale up this treatment globally​​.